News and blogs
166 results found.
The origins of childhood leukaemia in twins
Blood Cancer UK's research funding has led to an understanding of the origins of childhood leukaemia in twins.
New ‘universal approach’ therapy for leukaemia shows promise during world-first trial
Blood Cancer UK was proud to fund the lab studies that directly led to this life-changing trial which could broaden the number of people who benefit from this type of therapy in future.
Paxlovid rebound - what we know
Paxlovid rebound is when people recover from covid-19 after taking a course of Paxlovid tablets, but then the infection seems to come back. Find out what this means for people offered treatment with Paxlovid.
Evusheld available in the UK to buy privately
Evusheld is available privately in the UK. Here’s what we know about how to access it.
Health inequalities: how does stress change our bodies?
Read our blog about how social factors are more likely to impact certain groups.
Dr Sidney Farber's story
Read about Dr Sidney Farber who discovered the role folic acid played in the creation of leukaemia cells and achieved the first clinical remission of leukaemia in children by using a chemical anti agent.
What's the latest on Evusheld?
A look at the latest news on Evusheld
Five things we learned about blood cancer services from the cancer patient experience survey
Every year, NHS England asks thousands of cancer patients in England about their experiences. We've picked out five key things we think the NHS and Government should be focusing on, which we believe would save a significant number of lives.
People affected by blood cancer help decide what research we fund
For the first time at Blood Cancer UK, this year a group of 16 people affected by blood cancer reviewed all applications received by us for research funding.
Evusheld – is it effective?
In this blog, we talk about what the latest research is telling us about how effective Evusheld is.
Blood Cancer UK's research strategy
Since Blood Cancer UK was formed in 1960, it has invested over £500m in lifesaving blood cancer research.
This is Blood Cancer
Saturday 28 May is World Blood Cancer Day and we’re delighted to be able to share this new, hour-long documentary including films from Blood Cancer UK and other partners.
Our position on Evusheld
Since Evusheld was approved for use by MHRA, we’ve heard from the blood cancer community that one of their greatest concerns is the delay in its rollout across the UK. We wanted to address this directly and explain the work we’ve been doing.
We're funding 13 new research projects
Find out more about the latest blood cancer research projects that will receive £3 million pounds of funding from Blood Cancer UK
Find out more about the Covid antibody treatment Evusheld
The treatment consists of two long-acting antibodies called tixagevumab and cilgavimab.
Latest updates from the Covid-19 Vaccine Research Collaborative
Find out the latest information on the Covid-19 Vaccine Research Collaborative from Blood Cancer UK.
How did the third Covid vaccine dose roll-out go so badly wrong?
We take an in-depth look at a timeline of delays, missed opportunities, and mistakes which have caused huge anxiety among people with blood cancer – and may have even led to avoidable deaths.
Re-purposing drugs could revolutionise blood cancer treatment
Discover how re-purposing drugs could help bring new treatments to people with blood cancer.
Survival rates for children and young people with leukaemia and lymphoma sees big increase
Learn more about the increase of children and young people with lymphoma and leukaemia who are surviving and beating blood cancer.
Childhood blood cancer survival rates see big improvement
Read Blood Cancer UK's analysis on the improvements in childhood blood cancer survival rates.